Drugs / MRKAd5 HIV-1 gag/pol/nef vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00849680 | Apr 2003 → Mar 2005 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRKAd5 HIV-1 gag/pol/nef vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849680 ↗ |
| Known as | MRKAd 5 HIV-1 gag/pol/nef | “The goal of this study is to understand the safety, tolerability and immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd 5 HIV-1...” NCT00849680 ↗ |
| Modality | Vaccine | “Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)” NCT00849680 ↗ |
| Route | Intramuscular | “injected intramuscularly” NCT00849680 ↗ |